# Resveratrol reduces muscle atrophy and stress pathway activation in a combined disuse-hypoxia-mouse model

**Authors:** Aziz Ahmad Khan, Sajid Khan Sadozai, Fawad Ali, Nemat Khan, Rizwan Qaisar

PMC · DOI: 10.3389/fphar.2026.1753486 · Frontiers in Pharmacology · 2026-02-12

## TL;DR

Resveratrol helps protect mouse muscles from atrophy caused by disuse and low oxygen, potentially useful for muscle loss in space or clinical settings.

## Contribution

First demonstration of resveratrol's protective effects in a combined disuse and hypoxia muscle atrophy model.

## Key findings

- Resveratrol at 40 mg/kg nearly preserved muscle mass and strength under disuse and hypoxia.
- Resveratrol reduced activation of apoptosis, necroptosis, and ER stress pathways in affected muscles.
- Effects were specific to hindlimb unloaded animals and not observed in control groups.

## Abstract

Mechanical disuse and hypoxia synergistically worsen muscle atrophy by activating apoptosis, necroptosis, and ER stress pathways. While resveratrol, a natural polyphenol, has shown protective effects in isolated disuse or hypoxia models, its efficacy under combined conditions remains unclear.

Male C57BL/6J mice (4 months old) were assigned to ground control or hindlimb unloading (HU) groups under normoxia (21% O2) or hypoxia (15% O2) and treated daily with placebo or resveratrol (20 or 40 mg/kg) for two weeks. Muscle mass, grip strength, cling time, and gene expression of apoptotic, necroptotic, and ER stress markers were assessed.

HU-hypoxia significantly reduced muscle mass and function, with upregulation of stress-related genes. Resveratrol showed dose-dependent protection: 20 mg/kg modestly reduced atrophy, while 40 mg/kg nearly preserved muscle mass and strength to control levels under both normoxic and hypoxic conditions. To our knowledge, this is the first study to demonstrate protective effects of resveratrol in a combined HU and hypoxia model of muscle atrophy, accompanied by modulation of apoptosis, necroptosis and ER stress related gene expression.

These results suggest that resveratrol may decrease muscle degradation in fast twitch dominant muscles under combined disuse and hypoxia. However, these results are restricted to gastrocnemius muscle in mice, and further investigations in slow twitch muscles and clinical models are required before clinical relevance can be confirmed. These findings support its potential as a therapeutic agent for muscle loss in clinical and spaceflight settings, warranting further translational research.

Infographic displaying experimental outcomes for normoxic and hypoxic mice given placebo or resveratrol under ground control and hindlimb unloaded conditions. Resveratrol increases muscle weight and grip strength and decreases apoptosis, necroptosis, and ER stress only in hindlimb unloaded animals. Body weight remains unchanged across groups.

## Linked entities

- **Chemicals:** resveratrol (PubChem CID 5056)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Bax (BCL2-associated X protein) [NCBI Gene 12028], Mlkl (mixed lineage kinase domain-like) [NCBI Gene 74568] {aka 9130019I15Rik}, Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) [NCBI Gene 19766] {aka D330015H01Rik, RIP, RIP-1, Rinp, Rip1}, Xbp1 (X-box binding protein 1) [NCBI Gene 22433] {aka D11Ertd39e, TREB-5, TREB5, XBP-1}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Ripk3 (receptor-interacting serine-threonine kinase 3) [NCBI Gene 56532] {aka 2610528K09Rik, Rip3}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Casp1 (caspase 1) [NCBI Gene 12362] {aka ICE, Il1bc}, Atf4 (activating transcription factor 4) [NCBI Gene 11911] {aka Atf-4, C/ATF, CREB-2, CREB2, TAXREB67}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}
- **Diseases:** decline (MESH:D060825), atrophic (MESH:D020966), atrophy (MESH:D001284), cardiopulmonary disease (MESH:D006323), Muscle atrophy (MESH:D009133), inflammatory (MESH:D007249), mitochondrial dysfunction (MESH:D028361), muscle (MESH:D019042), bone fracture (MESH:D050723), muscle fiber (MESH:C563545), Hypoxia (MESH:D000860), hypoxic (MESH:D002534), major organ failure (MESH:D009102), stroke (MESH:D020521), COPD (MESH:D029424), necrosis (MESH:D009336), muscle degradation (MESH:D055959), CHF (MESH:D006333), muscle degeneration (MESH:D009410), muscle loss (MESH:D009135)
- **Chemicals:** saline (MESH:D012965), O2 (MESH:D010100), Resveratrol (MESH:D000077185), water (MESH:D014867), TRIzol (MESH:C411644), O2 (-), GC (MESH:C057580), DMSO (MESH:D004121), polyphenol (MESH:D059808), agarose (MESH:D012685)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Arachis hypogaea (goober, species) [taxon 3818], Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989], Fascellina sp. A (species) [taxon 1373661]
- **Cell lines:** /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936514/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936514/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12936514/full.md

---
Source: https://tomesphere.com/paper/PMC12936514